Mona Ashiya Sells 10,011 Shares of Disc Medicine, Inc. (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) Director Mona Ashiya sold 10,011 shares of the business’s stock in a transaction dated Friday, March 21st. The shares were sold at an average price of $54.00, for a total value of $540,594.00. Following the completion of the sale, the director now directly owns 187,297 shares of the company’s stock, valued at approximately $10,114,038. This trade represents a 5.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Mona Ashiya also recently made the following trade(s):

• On Wednesday, March 19th, Mona Ashiya sold 39,656 shares of Disc Medicine stock. The shares were sold at an average price of $54.02, for a total value of $2,142,217.12.
• On Wednesday, March 12th, Mona Ashiya sold 83,182 shares of Disc Medicine stock. The shares were sold at an average price of $54.45, for a total value of $4,529,259.90.
• On Monday, March 10th, Mona Ashiya sold 202,146 shares of Disc Medicine stock. The shares were sold at an average price of $54.29, for a total value of $10,974,506.34.

Disc Medicine Stock Performance

IRON stock opened at $52.24 on Friday. Disc Medicine, Inc. has a fifty-two week low of $25.60 and a fifty-two week high of $68.73. The business’s 50 day moving average price is $55.26 and its two-hundred day moving average price is $56.06. The company has a market capitalization of $1.81 billion, a price-to-earnings ratio of -13.13 and a beta of 0.73.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Thursday, February 27th. The company reported ($0.98) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.08. Sell-side analysts forecast that Disc Medicine, Inc. will post -4.07 earnings per share for the current year.

Analysts Set New Price Targets

IRON has been the subject of a number of recent research reports. TD Cowen assumed coverage on Disc Medicine in a research note on Thursday, February 27th. They issued a “buy” rating for the company. Wedbush reaffirmed an “outperform” rating and set a $90.00 price target (up previously from $83.00) on shares of Disc Medicine in a research report on Tuesday, January 21st. Morgan Stanley reaffirmed an “overweight” rating and set a $85.00 price target on shares of Disc Medicine in a research report on Friday, March 7th. Stifel Nicolaus upped their price target on Disc Medicine from $90.00 to $94.00 and gave the company a “buy” rating in a research report on Friday, January 24th. Finally, Scotiabank upped their price target on Disc Medicine from $73.00 to $75.00 and gave the company a “sector outperform” rating in a research report on Monday, March 3rd. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Disc Medicine presently has a consensus rating of “Buy” and an average target price of $93.80.

Institutional Trading of Disc Medicine

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. FMR LLC grew its stake in shares of Disc Medicine by 358.7% in the 4th quarter. FMR LLC now owns 1,866,248 shares of the company’s stock worth $118,320,000 after buying an additional 1,459,434 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Disc Medicine by 4.8% in the 3rd quarter. Wellington Management Group LLP now owns 1,840,226 shares of the company’s stock worth $90,429,000 after buying an additional 83,731 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Disc Medicine by 23.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,394,637 shares of the company’s stock worth $88,421,000 after buying an additional 262,690 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of Disc Medicine by 62.4% in the 4th quarter. Janus Henderson Group PLC now owns 1,217,815 shares of the company’s stock worth $77,170,000 after buying an additional 467,988 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Disc Medicine by 1.8% in the 4th quarter. Vanguard Group Inc. now owns 1,068,246 shares of the company’s stock worth $67,727,000 after buying an additional 18,716 shares during the last quarter. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.